Methods of use of anti-trem2 antibodies
AssigneeAlector LLC
InventorsMichael F. WARD, Sam JACKSON
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a TREM2 protein, e.g., human TREM2, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.
Claims47
A method of treating or delaying the progression of a disease or injury in an individual, wherein the individual is not homozygous for the ApoE e4 allele, the method comprising administering to the individual an anti-TREM2 agonist antibody.
3-4. (canceled)
(canceled)
(canceled)
14-22. (canceled)
(canceled)
(canceled)
(canceled)
35-38. (canceled)
(canceled)
42-43. (canceled)
(canceled)
48-50. (canceled)
52-53. (canceled)
55-66. (canceled)
69-72. (canceled)
74-76. (canceled)
Dependencies are inferred from the claim text.